Table 1.
Clinicopathologic Characteristics of pT1-3N0M0 Lung Adenocarcinoma Cohort (N=893)
| Characteristic | Median (Range) or N (%) |
|---|---|
| Age | 72 (36 – 92) |
| Gender | |
| Female | 559 (63%) |
| Male | 334 (37%) |
| Comorbidities | |
| Pulmonary | 220 (25%) |
| Cardiac | 492 (55%) |
| Pulmonary Function | |
| FEV1 (%) (N=872) | 94 (26 – 408) |
| Diffusion (%) (N=799) | 84.0 (24 – 165) |
| Time of Surgery (Tertile) | |
| 2000–2006 | 313 (35%) |
| 2007–2013 | 306 (34%) |
| 2014–2016 | 274 (31%) |
| Tumor Characteristics | |
| Tumor SUV (N=721) | 3.4 (0.5 – 9.8) |
| Tumor Size (cm) | 2.2 (0.2 – 9.0) |
| Predominant Histologic Subtype (N=765) | |
| Lepidic | 113 (15%) |
| Acinar | 361 (47%) |
| Papillary | 144 (19%) |
| Micropapillary | 27 (3.5%) |
| Solid | 109 (14%) |
| Other | 11 (1.4%) |
| Invasion | |
| Visceral Pleural Invasion (N=891) | 118 (13%) |
| Vascular Invasion (N=878) | 273 (31%) |
| Pathologic Tumor Stage (pT) | |
| 1a | 367 (41%) |
| 1b | 231 (26%) |
| 2a | 236 (26%) |
| 2b/3 | 52 (6.1%) |
| Driver Mutation | |
| EGFR (N=563) | 108 (19%) |
| KRAS (N=412) | 140 (34%) |
FEV1, forced expiratory volume in 1 second; pT, pathologic tumor; Tumor SUVmax, maximum standardized uptake value.